Analisis Keuangan Saham BDRX - Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) (NasdaqCM) Stock

Gambaran Umum

Biodexa Pharmaceuticals Plc is a biotechnological firm based in the United Kingdom, primarily engaged in the pharmaceuticals industry. The company specializes in the research, development, and commercialization of innovative drug therapies. A significant focus of Biodexa Pharmaceuticals is on developing treatments for diseases that currently have limited therapeutic options. Key projects include advanced-stage clinical trials for new oncology drugs, which aim to address various forms of cancer with novel mechanisms of action. Additionally, the company has made strides in the neurodegenerative disease space, emphasizing breakthrough treatments for conditions such as Alzheimer's and Parkinson's disease. Biodexa Pharmaceuticals continues to expand its research capabilities and forge strategic partnerships to accelerate drug development and access global markets.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) per 2024 Dec 31 adalah -9.20 MM.
Nilai net income untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) per 2024 Dec 31 adalah -5.73 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-12-31		-9.20	-5.73
2024-09-30	0.04	-7.94	-6.27
2024-06-30	0.08	-6.58	-6.82
2024-03-31	0.23	-6.59	-6.95
2023-12-31	0.38	-6.70	-7.08
2023-09-30	0.46	-8.73	-7.62
2023-06-30	0.53	-8.04	-8.16
2023-03-31	0.61	-7.80	-7.91
2022-12-31	0.70	-8.93	-7.66
2022-09-30	0.67	-7.56	-6.51
2022-06-30	0.65	-7.54	-5.37
2022-03-31	0.61	-7.27	-5.41
2021-12-31	0.58	-7.00	-5.46
2021-09-30	0.58	-8.30	-6.69
2021-06-30	0.58	-4.69	-7.92
2021-03-31	0.46	-6.45	-15.06
2020-12-31	0.34	-10.67	-22.19

Laporan Laba Rugi: EPS

earnings per share basic untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -11.57.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-12-31	-11.57
2024-09-30	-18.29	-18.29
2024-06-30	-35.76	-35.76
2024-03-31	-62.53	-62.53
2023-12-31	-224.13
2023-09-30	-414.25	-414.25
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) per 2024 Dec 31 adalah -12.26 MM.
Nilai cash from investing activities untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) per 2024 Dec 31 adalah -0.60 MM.
Nilai kas dari aktivitas pendanaan untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) per 2024 Dec 31 adalah 8.56 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-12-31	-12.26	-0.60	8.56
2024-09-30	-10.01	-0.82	8.59
2024-06-30	-7.75	-1.04	8.62
2024-03-31	-7.29	-0.65	9.42
2023-12-31	-6.83	-0.27	10.23
2023-09-30	-7.11	-0.22	8.30
2023-06-30	-7.39	-0.18	6.38
2023-03-31	-7.22	-0.20	3.21
2022-12-31	-7.05	-0.22	0.05
2022-09-30	-6.74	-0.18	4.43
2022-06-30	-6.44	-0.15	8.81
2022-03-31	-6.22	-0.21	8.81
2021-12-31	-6.01	-0.28	8.80
2021-09-30	-5.66	1.12	5.71
2021-06-30	-5.32	2.52	2.62
2021-03-31	-7.31	2.54	2.85
2020-12-31	-9.30	2.57	3.08

Metrik Penilaian: PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31

Efektivitas Manajemen

roa untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -0.65.
roe untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -1.46.
roic untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -0.75.
croic untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -0.02.
ocroic untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -0.85.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2024-12-31	-0.65	-1.46	-0.75	-0.02	-0.85
2024-09-30	-0.65	-1.46	-0.75	-0.02	-0.85
2024-06-30	-0.89	-1.34	-1.38	0.61	-1.33
2024-03-31	-1.48	-2.58
2023-12-31	-1.48	-2.58	-1.30	0.17	-1.22
2023-09-30	-0.84	-1.09	-1.40	-0.20	-1.26
2023-06-30	-0.84	-1.09	-1.40	-0.20	-1.26
2023-03-31	-0.82	-1.06	-1.35	-0.72	-1.24
2022-12-31	-0.50	-0.62	-1.72	-0.66	-1.78
2022-09-30	-0.50	-0.62	-1.72	-0.66	-1.78
2022-06-30	-0.65	-1.43	-0.65	0.27	-0.78
2022-03-31	-0.65	-1.44	-0.66	0.29	-0.76
2021-12-31	-0.56	-0.81	-0.49	0.22	-0.54
2021-09-30	-0.68	-1.00	-0.60	0.11	-0.50
2021-06-30	-0.66	-1.74	-1.70	-0.03	-1.14
2021-03-31	-1.25	-3.31	-3.22	-0.38	-1.57
2020-12-31	-0.72	-1.13	-3.18	-0.48	-1.33

Gross Margins

marjin kotor untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah 1.75.
marjin bersih untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -82.16.
marjin operasi untuk Biodexa Pharmaceuticals Plc - Depositary Receipt (Common Stock) pada 2024 Dec 31 adalah -79.31.

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2024-12-31	1.75	-82.16	-79.31
2024-09-30	1.75	-82.16	-79.31
2024-06-30	-9.67	-18.58	-21.03
2024-03-31	-8.36	-15.43	-17.77
2023-12-31	-8.36	-15.43	-17.77
2023-09-30	-8.36	-15.43	-17.77
2023-06-30	-8.36	-15.43	-17.77
2023-03-31	-7.19	-12.88	-14.93
2022-12-31	-6.57	-9.69	-12.26
2022-09-30	-6.57	-9.69	-12.26
2022-06-30	-6.84	-8.32	-11.69
2022-03-31	-6.94	-8.85	-11.89
2021-12-31	-7.05	-9.45	-12.11
2021-09-30	-3.86	-11.60	-8.74
2021-06-30	-0.65	-13.76	-5.37
2021-03-31	-4.74	-32.77	-12.30
2020-12-31	-11.62	-64.69	-23.94